JPH04364839A - Rod for closing lacrimal duct - Google Patents
Rod for closing lacrimal ductInfo
- Publication number
- JPH04364839A JPH04364839A JP3140053A JP14005391A JPH04364839A JP H04364839 A JPH04364839 A JP H04364839A JP 3140053 A JP3140053 A JP 3140053A JP 14005391 A JP14005391 A JP 14005391A JP H04364839 A JPH04364839 A JP H04364839A
- Authority
- JP
- Japan
- Prior art keywords
- rod
- lacrimal
- lacrimal duct
- closing
- polyglycolic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920000954 Polyglycolide Polymers 0.000 claims description 15
- 239000004633 polyglycolic acid Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 abstract description 4
- 238000003780 insertion Methods 0.000 abstract description 3
- 230000037431 insertion Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract 1
- 208000037921 secondary disease Diseases 0.000 abstract 1
- 229950008885 polyglycolic acid Drugs 0.000 description 14
- 238000000034 method Methods 0.000 description 7
- 241000083513 Punctum Species 0.000 description 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002729 catgut Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- -1 collagen Natural products 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
- ODNBVEIAQAZNNM-UHFFFAOYSA-N 1-(6-chloroimidazo[1,2-b]pyridazin-3-yl)ethanone Chemical compound C1=CC(Cl)=NN2C(C(=O)C)=CN=C21 ODNBVEIAQAZNNM-UHFFFAOYSA-N 0.000 description 1
- HSQFVBWFPBKHEB-UHFFFAOYSA-N 2,3,4-trichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1Cl HSQFVBWFPBKHEB-UHFFFAOYSA-N 0.000 description 1
- GUNJVIDCYZYFGV-UHFFFAOYSA-K Antimony trifluoride Inorganic materials F[Sb](F)F GUNJVIDCYZYFGV-UHFFFAOYSA-K 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は、涙道閉鎖用ロッドに関
する。更に詳しくは、溶解性の涙道閉鎖用ロッドに関す
る。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a lacrimal duct closure rod. More specifically, the present invention relates to a dissolvable lacrimal duct closing rod.
【０００２】0002
【従来の技術】人間の日常生活において涙の役割は重要
である。目の乾燥を防ぎ、目に入ったゴミ等の異物を洗
い流すほか、殺菌作用も持っており、涙が減るとこれら
の働きが低下して角膜炎や結膜炎等の病気にかかりやす
くなることは周知の事実である。BACKGROUND OF THE INVENTION Tears play an important role in human daily life. In addition to preventing dryness of the eyes and washing away foreign substances such as dust that have entered the eyes, it also has a bactericidal effect, and it is well known that when tear production decreases, these functions decrease, making you more susceptible to diseases such as keratitis and conjunctivitis. This is a fact.
【０００３】また、近年の傾向として、テレビ画面を長
時間見つめるコンピューター作業従事者にドライアイ（
涙液減少症）患者が増えているとも言われている。涙腺
より分泌された涙液は角膜表面をぬらした後、鼻側に流
れ涙点に入り、涙小管、涙のう、鼻涙管を通って下鼻道
に流れ出る。この涙点から下鼻道に至るまでを涙道とい
う。Additionally, as a recent trend, computer workers who stare at television screens for long periods of time are experiencing dry eye (
It is also said that the number of patients with lachrymal hypolacrima is increasing. After wetting the corneal surface, the lacrimal fluid secreted by the lacrimal gland flows toward the nose, enters the lacrimal punctum, and flows out into the lower nasal passage through the lacrimal canaliculus, lacrimal sac, and nasolacrimal duct. The area from this lacrimal punctum to the inferior nasal meatus is called the lacrimal duct.
【０００４】上記した様なドライアイ患者に対して、涙
道より流出する涙液量を減らす方法が提案されている。
例えば米国特許第３９４９７５０号明細書に記載された
ような涙点プラグがある。この方法は涙道の入口に栓を
して涙液の流出を止めようというものである。この方法
によれば、プラグの上部が、涙点から外に出ているため
この部分が角膜にふれ、角膜に擦傷を起こすことがある
とともに、涙点より外れ易いといった欠点を有する。ま
た特開昭６１−１１５５５９号公報には、カットグット
のロッドを、涙道に挿入することが提案されている。カ
ットグットすなわちコラーゲンは涙道に挿入後、１０〜
１５日間で溶けてしまうので、プラスチックロッドを挿
入した時の様な長期滞留によるトラブルの心配の無い方
法であるが、コラーゲンは、天然の動物の腸などを原料
とするので用いられる組織の性質と自然の生物学的変化
により、きめ、および溶解速度のバラツキが大きいとい
った欠点がある。加えて、コラーゲンは抗原抗体反応が
起こりやすく生体適合性に問題があることは周知の事実
である。[0004] For the dry eye patients described above, methods have been proposed to reduce the amount of lachrymal fluid flowing out from the lacrimal duct. For example, there are punctal plugs, such as those described in US Pat. No. 3,949,750. This method involves placing a plug at the entrance of the tear duct to stop the flow of tear fluid. According to this method, since the upper part of the plug protrudes from the lacrimal punctum, this part comes into contact with the cornea, which may cause corneal abrasion, and it also has the disadvantage that it is easily removed from the lacrimal punctum. Furthermore, Japanese Patent Application Laid-open No. 115559/1983 proposes inserting a catgut rod into the lacrimal duct. Catgut or collagen is inserted into the lachrymal canal for 10~
This method dissolves in 15 days, so there is no need to worry about the problems caused by long-term retention like when inserting a plastic rod. However, since collagen is made from natural animal intestines, it depends on the nature of the tissue used. Disadvantages include large variations in texture and dissolution rate due to natural biological changes. In addition, it is a well-known fact that collagen is susceptible to antigen-antibody reactions and has biocompatibility problems.
【０００５】[0005]
【発明が解決しようとする課題】本発明は、上述のよう
な、使用時に発生する二次的な弊害が起こらない、均一
な溶解性を有する、溶解速度のバラツキの小さい涙道閉
鎖用ロッドを提供することを目的とする。[Problems to be Solved by the Invention] The present invention provides a rod for lacrimal duct closure that does not cause the secondary adverse effects that occur during use, has uniform solubility, and has small variations in dissolution rate. The purpose is to provide.
【０００６】[0006]
【課題を解決するための手段】本発明者等は、この様な
問題を解決するために各種材料に関し鋭意検討した結果
、ポリグリコール酸が涙道内で溶解することを見出し本
発明に至った。ポリグリコール酸は、縫合糸用の材料と
して比較的よく知られた材料であり、生体組織内に於い
て溶解することは知られている。しかし必ずしも生体組
織内とは言えない涙道に於いて溶解するということは意
外なことであった。[Means for Solving the Problems] In order to solve the above-mentioned problems, the present inventors conducted intensive studies on various materials, and as a result, they discovered that polyglycolic acid dissolves within the lachrymal duct, leading to the present invention. Polyglycolic acid is a relatively well-known material for sutures, and is known to dissolve in living tissue. However, it was surprising that it dissolves in the lacrimal duct, which is not necessarily in living tissue.
【０００７】すなわち本発明は、ポリグリコール酸より
なる涙道閉鎖用ロッドである。涙道閉鎖用ロッドは涙点
より挿入するが、その大きさは通常、長さ０．５〜５ｍ
ｍ、直径０．１〜１．５ｍｍの範囲から選択されるが、
長さ１．０〜３．０ｍｍ、直径０．２〜０．８ｍｍが最
も一般的である。これは各個人の涙点の大きさ等により
選択すべきものであり、使用するに際して、ロッドの最
適長さ、および半径を使用する人に合わせて決定すれば
よい。That is, the present invention is a lacrimal duct closing rod made of polyglycolic acid. The lacrimal duct closure rod is inserted through the lacrimal punctum, and its size is usually 0.5 to 5 m in length.
m, selected from the range of 0.1 to 1.5 mm in diameter,
The most common length is 1.0-3.0 mm and the diameter is 0.2-0.8 mm. This should be selected depending on the size of the puncta of each individual, and the optimal length and radius of the rod may be determined depending on the person using the rod.
【０００８】本発明に係る化合物であるポリグリコール
酸は通常公知の方法でグリコリドの開環重合により製造
される。これを反応式で表せば下記化１に示すとおりで
ある。[0008] Polyglycolic acid, which is a compound according to the present invention, is produced by ring-opening polymerization of glycolide using a generally known method. This can be expressed as a reaction formula as shown in Chemical Formula 1 below.
【０００９】[0009]
【化１】[Chemical formula 1]
【００１０】ここに用いるポリグリコール酸の分子量は
少なくとも約１００００（重合度ｘ＝約１５０）（以下
約を略す）を有し、４００００から７００００（ｘ＝６
９０〜１２００）の間を有するものが好ましい。分子量
が１００００未満であると、溶融成形が不可能であり、
７００００以上になると粘度が大きくなり成形が困難と
なる。分子量が１００００〜１０００００のポリグリコ
ール酸の製造方法は、例えば、米国特許第２６６８１６
２号明細書や特公昭４３−５１９２号公報などに記載さ
れており、通常実施されている概略を述べると次の通り
である。The molecular weight of the polyglycolic acid used here is at least about 10,000 (degree of polymerization
90 to 1200) is preferred. If the molecular weight is less than 10,000, melt molding is impossible;
When it exceeds 70,000, the viscosity increases and molding becomes difficult. A method for producing polyglycolic acid having a molecular weight of 10,000 to 100,000 is described, for example, in US Pat. No. 266,816.
It is described in the specification of No. 2, Japanese Patent Publication No. 43-5192, and the like, and the outline of the commonly practiced method is as follows.
【００１１】オキシ酢酸（グリコール酸）から調製した
グリコリドを三フッ化アンチモン触媒（０．０３％対グ
リコリド）の存在下で加熱し１９５℃で１時間以上、さ
らに２３０℃で３０分加熱すると、ポリグリコール酸が
得られる。分子量は１００００から１０００００の間に
あり、このような分子量の重合体の２４５℃の溶融粘度
は約４００から２７０００ポイズの間にある。When glycolide prepared from oxyacetic acid (glycolic acid) is heated in the presence of an antimony trifluoride catalyst (0.03% to glycolide) at 195°C for over 1 hour and then further heated at 230°C for 30 minutes, poly Glycolic acid is obtained. The molecular weight is between 10,000 and 100,000, and the melt viscosity at 245°C of a polymer of such molecular weight is between about 400 and 27,000 poise.
【００１２】なお、ポリグリコール酸の分子量は、フェ
ノール−トリクロロフェノール混合溶媒に溶解させて、
末端基定量法により平均分子量として測定することがで
きる。このようにして得られたポリグリコール酸をプラ
ンジャー押出機等を用い溶融紡糸し冷却固化した後これ
を所望の長さにカットすることによりポリグリコール酸
ロッドを得ることができる。[0012] The molecular weight of polyglycolic acid is determined by dissolving it in a mixed solvent of phenol and trichlorophenol.
It can be measured as an average molecular weight using the terminal group quantitative method. A polyglycolic acid rod can be obtained by melt-spinning the thus obtained polyglycolic acid using a plunger extruder or the like, cooling and solidifying it, and then cutting it into a desired length.
【００１３】このようにして得られた涙道閉鎖用ロッド
は、コラーゲンのような天然物を素材としないことから
、自然界の生物学的影響により発生する不利益、例えば
溶解性の不均一性等は大巾に改善されている。また、ポ
リグリコール酸を安定化させる目的で、例えば特公昭６
２−４１５２５号公報に記載されるようなポリグリコー
ル酸の末端基をエステル化したような化合物によってな
る涙道閉鎖用ロッドも本発明に含まれることは言うまで
もない。[0013] Since the rod for lacrimal duct closure obtained in this manner is not made of natural products such as collagen, it is free from disadvantages caused by biological influences in nature, such as non-uniform solubility. has been greatly improved. In addition, for the purpose of stabilizing polyglycolic acid, for example,
Needless to say, the present invention also includes a lacrimal duct closing rod made of a compound obtained by esterifying the terminal group of polyglycolic acid as described in Japanese Patent No. 2-41525.
【００１４】また挿入時の取扱い性を改良する目的で、
各種界面活性剤、例えばステアリン酸カルシウムの様な
コーティング剤によってコートして用いることも可能で
ある。また、トリフェニルホスファイト、ジアルキルフ
ェノールスルファイド、二硫化芳香族フェノールに例示
されるような安定剤を添加することもできる。[0014] Also, for the purpose of improving handling during insertion,
It can also be used by coating with various surfactants, for example, coating agents such as calcium stearate. Further, stabilizers such as triphenyl phosphite, dialkylphenol sulfide, and disulfide aromatic phenol may be added.
【００１５】また、所望により適当な着色剤により着色
することも可能である。[0015] Furthermore, it is also possible to color with a suitable coloring agent if desired.
【００１６】[0016]
【実施例】次に実施例により本発明をさらに詳細に説明
する。EXAMPLES Next, the present invention will be explained in more detail with reference to Examples.
【００１７】[0017]
【実施例１】米国特許第２６６８１６２号明細書に記載
の方法でグリコリドより得た数平均分子量３００００の
ポリグリコール酸粉末を、プランジャー押出機に挿入し
２３０℃で溶融紡糸し、水中に導き冷却固化したものを
回転刃付カッターにより連続的にカットし、直径０．３
ｍｍ、長さ２ｍｍのポリグリコール酸よりなる涙道閉鎖
用ロッドを得た。[Example 1] Polyglycolic acid powder with a number average molecular weight of 30,000 obtained from glycolide by the method described in US Pat. No. 2,668,162 was inserted into a plunger extruder, melt-spun at 230°C, and then introduced into water and cooled. The solidified material is cut continuously using a cutter with a rotating blade, and the diameter is 0.3.
A lacrimal duct closure rod made of polyglycolic acid and having a length of 2 mm and a length of 2 mm was obtained.
【００１８】このロッドを２つに切り１ｍｍ長のロッド
にしたものを、体重３．５Ｋｇ、および３．４Ｋｇの二
羽の白色ウサギの左右の涙点より挿入した。１．５ケ月
後、涙道を切開したところ、挿入したロッドは、溶解消
失していた。[0018] This rod was cut into two, each having a length of 1 mm, and the rods were inserted into the left and right lacrimal puncta of two white rabbits weighing 3.5 kg and 3.4 kg. When the lacrimal duct was incised 1.5 months later, the inserted rod had dissolved and disappeared.
【００１９】[0019]
【発明の効果】本発明の涙道閉鎖用ロッドを使用するこ
とにより、ドライアイ症状が軽減され、溶解速度が均一
であることから挿入スケジュール管理が容易であり、加
えて生体適合性に関する不安も軽減される。[Effects of the Invention] By using the lacrimal duct closure rod of the present invention, dry eye symptoms are alleviated, and the dissolution rate is uniform, making it easy to manage insertion schedules, and in addition, concerns regarding biocompatibility are alleviated. Reduced.
Claims (1)
ロッド。Claim: 1. A lacrimal duct closure rod made of polyglycolic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3140053A JPH04364839A (en) | 1991-06-12 | 1991-06-12 | Rod for closing lacrimal duct |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3140053A JPH04364839A (en) | 1991-06-12 | 1991-06-12 | Rod for closing lacrimal duct |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04364839A true JPH04364839A (en) | 1992-12-17 |
Family
ID=15259895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3140053A Withdrawn JPH04364839A (en) | 1991-06-12 | 1991-06-12 | Rod for closing lacrimal duct |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04364839A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010508995A (en) * | 2006-11-09 | 2010-03-25 | アルコン リサーチ， リミテッド | Puncture plug containing water-insoluble polymer matrix |
| US8632809B2 (en) | 2006-11-09 | 2014-01-21 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
-
1991
- 1991-06-12 JP JP3140053A patent/JPH04364839A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010508995A (en) * | 2006-11-09 | 2010-03-25 | アルコン リサーチ， リミテッド | Puncture plug containing water-insoluble polymer matrix |
| US8632809B2 (en) | 2006-11-09 | 2014-01-21 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gottanka et al. | Correlation of pseudoexfoliative material and optic nerve damage in pseudoexfoliation syndrome. | |
| Girard | Pars plana phacoprosthesis (aphakic intraocular implant): a preliminary report | |
| JP3486758B2 (en) | Injectable lacrimal canaliculus | |
| DE69905871T2 (en) | USE OF A DYE TO EASIER LENS EXTRACTION IN CATARACT | |
| Wilson | Congenital iris ectropion and a new classification for anterior segment dysgenesis | |
| Kooner et al. | Intraocular pressure following ECCE, phacoemulsification, and PC-IOL implantation | |
| Crawford et al. | Preliminary evaluation of a hydrogel core-and-skirt keratoprosthesis in the rabbit cornea | |
| Zwaan et al. | Morphogenesis of the eye lens in a mouse strain with hereditary cataracts | |
| Bischoff et al. | High blood pressure in choroidal arteries as a possible pathogenetic mechanism in senile macular degeneration | |
| Richardson et al. | Exfoliation Glaucoma: Quantitative Perfusion and Ultrastructural Study | |
| JPH04364839A (en) | Rod for closing lacrimal duct | |
| Hirata et al. | Lacquer crack lesions in experimental chick myopia | |
| Alpar | Sodium hyaluronate (Healon®) in glaucoma filtering procedures | |
| Lazenby et al. | The use of sodium hyaluronate (Healon) in intracapsular cataract extraction with insertion of anterior chamber intraocular lenses | |
| JPH04364857A (en) | Rod for blocking lacrimal duct | |
| JPH04364856A (en) | Rod for blocking lacrimal liquid | |
| Speakman et al. | Site of obstruction to aqueous outflow in chronic simple glaucoma | |
| JPH04364842A (en) | Rod for insertion into lacrimal duct | |
| JPH0592015A (en) | Rod for preventing outflow of tears | |
| Ophir et al. | Encapsulated filtering bleb and subconjunctival 5-fluorouracil | |
| Daniel | Healing of the iris in rabbits following experimental iridectomy | |
| LEWALLEN | Aniridia and related iris defects: a report of twelve cases with bilateral cataract extraction and resulting good vision in one | |
| JPH0592016A (en) | Rod for damming up outflow of tears | |
| Babizhayev et al. | Clinical, structural and molecular phototherapy effects of laser irradiation on the trabecular meshwork of human glaucomatous eyes | |
| Korobelnik et al. | Expanded polytetrafluoroethylene episcleral implants used as encircling scleral buckling: an experimental and histopathological study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 19980903 |